Skip to main content

Sigma-Aldrich Q4 Revenues Increase 3 Percent Despite Negative Currency Effects

NEW YORK (GenomeWeb) – Sigma-Aldrich today reported a 3 percent year-over-year increase in its fourth quarter sales. 

For the three months ended Dec. 31, 2014, the firm posted $705 million in sales, up from $684 million a year ago, beating the average analysts' estimate of $694.6 million. Organically, sales were up 7 percent year over year. Currency effects reduced sales by 5 percent, while acquisitions and divestitures increased sales by 1 percent, the St. Louis-based firm said. 

By business unit, Research sales retreated to $341 million from $347 million in Q4 2013, Applied sales grew to $167 million from $156 million, and SAFC Commercial sales were up to $197 million from $181 million. 

Sigma-Aldrich recorded a profit of $133 million, or $1.11 per share, in Q4 2014, compared to a profit of $131 million, or $1.08 per share, in the year ago period. On an adjusted basis, the company had EPS of $1.14, surpassing the consensus Wall Street expectation of $1.09. 

Its R&D spending was down 6 percent to $16 million for the quarter from $17 million a year ago, while its SG&A costs rose 10 percent to $170 million from $154 million. Sigma-Aldrich also posted $7 million in other charges for the recently completed quarter, compared to none a year ago. 

For full-year 2014, the company had sales of $2.79 billion, up 3 percent from $2.70 billion in 2013, and nudging past the average analysts' estimate of $2.77 billion. Sales grew 4 percent on an organic basis, while currency effects tamped down sales by 1 percent, Sigma-Aldrich said. 

The Research business unit posted $1.40 billion in revenues, the same as in 2013, while Applied sales of $680 million was up from $629 million a year ago. SAFC Commercial sales improved to $701 million from $673 million. 

The company's net profit of $500 million, or $4.17 per share, was up from a profit of $491 million or $4.06 per share, in 2013. Its adjusted EPS of $4.37 beat the consensus Wall Street estimate of $4.31. 

Its R&D costs narrowed 2 percent year over year to $65 million from $66 million, and its SG&A costs grew 4 percent to $639 million from $612. Other charges for the year increased 55 percent to $34 million from $22 million in 2013. 

Sigma-Aldrich finished 2014 with $958 million in cash and cash equivalents. 

The firm is in the process of being acquired by Merck KGaA for $17 billion, and Sigma-Aldrich President and CEO Rakesh Sachdev said in a statement today that the deal remains on track for completion by mid-year. 

"We believe that our 80-year mission of enabling science to improve the quality of life by providing one of the broadest portfolios of high-quality products in the industry will significantly benefit the combination of the two companies, our employees and, most importantly, our large world-wide customer base," he said. 

The company said that this week its board approved a quarterly cash dividend of $.23 per share to be paid on March 13 to shareholders of record on Feb. 27. 

In early morning trading on the Nasdaq today, Sigma-Aldrich's shares were up less than 1 percent at $138.21.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.